Orthopedic Devices are used to treat the disorders and injuries of the musculoskeletal system of human body. Orthobiologics are biomaterials used in orthopedic surgery as an adjunct to faster fusion and healing of the bone. Soft Tissue Biologics are used in surgical interventions to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. GlobalData uses proprietary data and analytics to provide a comprehensive report on the soft tissue biologics market in Finland. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the soft tissue biologics market in Finland was Stryker followed by AlloSource, Smith & Nephew, Surgalign, LifeNet Health, ConMed, Arthrex and Zimmer Biomet.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
Soft Tissue Biologics focuses on the repair of the Anterior Cruciate Ligament (ACL), Posterior Cruciate Ligament (PCL), Rotator Cuff, and Achilles’s tendon. Other indications include Medial Collateral Ligament (MCL), Lateral Collateral Ligament (LCL), Medial Patellofemoral Ligament (MPFL), Ulnar Collateral Ligament (UCL), flexor tendon, and hip flexor repair. Soft tissue biologics can be either Tendon Grafts/Reinforcements or Tendon Wrapping products. Tendon Grafts or reinforcements are meant to provide structural aid to or replacement of the damaged tendon in order to restore normal function. Tendon Wrapping is a form of surgical tendon repair where a small sheet of tissue that acts as a physical barrier between the repair site and the surrounding space, providing a low friction environment for the tendon to heal and operate within.
The soft tissue biologics market in Finland can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size soft tissue biologics in Finland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
